Safety and Reactogenicity of a Malaria Vaccine in Kenyan Children
Author Information
Author(s): Withers Mark R, McKinney Denise, Ogutu Bernhards R, Waitumbi John N, Milman Jessica B, Apollo Odika J, Allen Otieno G, Tucker Kathryn, Soisson Lorraine A, Diggs Carter, Leach Amanda, Wittes Janet, Dubovsky Filip, Stewart V. Ann, Remich Shon A, Cohen Joe, Ballou W. Ripley, Holland Carolyn A, Lyon Jeffrey A, Angov Evelina, Stoute José A, Martin Samuel K, Heppner D. Gray Jr.
Primary Institution: United States Army Medical Research Unit–Kenya
Hypothesis
The study aimed to evaluate the safety, reactogenicity, and immunogenicity of an investigational malaria vaccine in children.
Conclusion
The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed children aged 12 to 47 months, with higher immune responses observed at 25 and 50 μg doses compared to 10 μg.
Supporting Evidence
- Both vaccines were safe and well tolerated.
- FMP1/AS02A recipients experienced significantly more pain and injection-site swelling.
- Anti-FMP1 antibody titers increased in a dose-dependent manner.
- Subjects receiving 25 or 50 μg of FMP1 had significantly higher antibody levels than those receiving the comparator.
- A longitudinal mixed effects model showed a statistically significant effect of dosage level on immune response.
Takeaway
The malaria vaccine tested was safe for young children and helped their bodies make antibodies to fight malaria.
Methodology
This was a phase Ib, double-blind, randomized, controlled, dose-escalation trial with 135 children receiving different doses of the malaria vaccine or a comparator.
Potential Biases
Randomization procedures were appropriate, but the small sample size may limit the generalizability of the findings.
Limitations
The study had a small sample size and was not powered to detect small differences in adverse events.
Participant Demographics
Participants were 135 children aged 12-47 months, primarily from the Luo ethnic group in western Kenya.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI of 1.7, 3.2
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website